Mouse anti-Human PD-L1/B7-H1 Monoclonal Antibody | anti-PD-L1/B7-H1 antibody

Anti-PD-L1/B7-H1 Antibody, Mouse Monoclonal

Cat. Num. AAA258733

• Reactivity: Human
• Applications: Immunohistochemistry
• Purity: Protein A
• Synonyms: PD-L1/B7-H1, Antibody; Anti-PD-L1/B7-H1 Antibody, Mouse Monoclonal; CD274 molecule; Anti-B7-H Antibody; Anti-B7-H1 Antibody; Anti-B7H1 Antibody; Anti-PD-L1 Antibody; Anti-PDCD1L1 Antibody; Anti-PDCD1LG1 Antibody; Anti-PDL1 Antibody; anti-PD-L1/B7-H1 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Mouse IgG1
• Clone Number: #62
• Specificity: Human PD-L1
• Purity/Purification: Protein A
• Form/Format: Liquid; 0.2um filtered solution in PBS

• Applicable Applications for anti-PD-L1/B7-H1 antibody: IHC (Immunohistochemistry)
• Immunogen: Full length human CD274 expression plasmid
• Preparation: This product is a recombinant monoclonal antibody expressed from HEK293 cells.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.

IHC (Immunohiostchemistry)

(Immunochemical staining of human CD274 in human placenta with mouse monoclonal antibody at 1:20000 dilution, formalin-fixed paraffin embedded sections.)

IHC (Immunohistochemistry)

(Immunochemical staining of human CD274 in human breast carcinoma with mouse monoclonal antibody at 1:20000 dilution, formalin-fixed paraffin embedded sections.)

Related Product Information for anti-PD-L1/B7-H1 antibody

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

References

Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.